SCHEMBL3963784

SCHEMBL3963784

Cc1cc(C(=O)Nc2cc(CNCCc3ccccc3)ccc2N2CCC(C(N)=O)CC2)no1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.49
MAPT P10636 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GPR6 P46095 1/20 0.44
CYP1A2 P05177 2/20 0.42
CYP2D6 P10635 2/20 0.42
CYP2C19 P33261 2/20 0.42
SYK P43405 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.42
LMNA P02545 2/20 0.41
PTGS2 P35354 1/20 0.41
ACKR3 P25106 1/20 0.40
SRPK1 Q96SB4 1/20 0.40
HTT P42858 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
KDM4E B2RXH2 1/20 0.38
CXCR3 P49682 1/20 0.37
NPC1 O15118 1/20 0.37
TP53 P04637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3957616 0.91 MAPT (0.49) ALDH1A1MAPTL3MBTL1GPR6CYP1A2
SCHEMBL5005627 0.85 MAPT (0.49) ALDH1A1MAPTL3MBTL1GPR6CYP1A2
SCHEMBL3960759 0.85 MAPT (0.49) ALDH1A1MAPTL3MBTL1GPR6CYP1A2
SCHEMBL3963200 0.82 MAPT (0.49) ALDH1A1MAPTL3MBTL1GPR6CYP1A2
SCHEMBL3955325 0.81 CYP1A2 (0.41) ALDH1A1MAPTL3MBTL1CYP1A2CYP2D6
SCHEMBL3879025 0.79 LMNA (0.55) MAPTCYP1A2CYP2D6CYP2C19LMNA
SCHEMBL3963780 0.78 CYP1A2 (0.44) ALDH1A1MAPTL3MBTL1CYP1A2CYP2D6
SCHEMBL4237950 0.77 ALDH1A1 (0.50) ALDH1A1CYP2D6CYP2C19LMNAHTT
SCHEMBL5002946 0.76 ALDH1A1 (0.48) ALDH1A1MAPTL3MBTL1GPR6CYP1A2
SCHEMBL5002942 0.76 ALDH1A1 (0.48) ALDH1A1MAPTL3MBTL1GPR6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079525-A1 CALCIUM RECEPTOR MODULATING AGENTS Amgen Inc. (US) 2009-07-22 EP disclosed
US-20080221101-A1 Calcium receptor modulating agents AMGEN INC. (US) 2008-09-11 US disclosed
WO-2008057282-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. (US) 2008-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221101-A1 Calcium receptor modulating agents CASR, RYR1, RYR2 ALDH1A1 3089/4885MAPT 2193/4885L3MBTL1 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.